Trial: 202008120

A Phase 3, Open-Label, Multicenter, Randomized, Active-controlled Study to Assess Pharmacokinetics and Compare the Efficacy, Safety and Tolerability of P1101 vs Anagrelide as Second Line Therapy for Essential Thrombocythemia

Phase

III

Principal Investigator

Oh, Stephen

Disease Site

Bone Marrow Transplant; Other Hematopoietic

Learn more about this study at: clinicaltrials.gov